Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.60 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.60 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.60 |
| ▸ | AXL | P30530 | 13/20 | 0.56 |
| ▸ | MERTK | Q12866 | 11/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 9/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25416279 | 0.93 | MET (0.70) | METRIPK2RIPK1RIPK3AXL | |
| SCHEMBL25365740 | 0.92 | MET (0.68) | METRIPK2RIPK1RIPK3AXL | |
| SCHEMBL25365534 | 0.92 | MET (0.83) | METRIPK2RIPK1RIPK3AXL | |
| SCHEMBL25414382 | 0.90 | MET (0.65) | METRIPK2RIPK1RIPK3AXL | |
| SCHEMBL26317418 | 0.89 | RIPK3 (0.77) | METRIPK2RIPK1RIPK3AXL | |
| SCHEMBL25366801 | 0.87 | MET (0.72) | METRIPK2RIPK1RIPK3AXL | |
| SCHEMBL25366935 | 0.85 | MET (0.70) | METRIPK2RIPK1RIPK3AXL | |
| SCHEMBL25360414 | 0.84 | AXL (0.70) | METAXLMERTKTYRO3 | |
| SCHEMBL25366261 | 0.84 | MET (0.81) | METRIPK2RIPK1RIPK3AXL | |
| SCHEMBL26033156 | 0.84 | MET (0.71) | METRIPK2RIPK1RIPK3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, MET, AXL | MET 2/4885RIPK2 1519/4885RIPK1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.